Cargando…

The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis

Chronic pancreatitis (CP) is a chronic progressive inflammatory disease of the pancreas, caused by multiple factors and accompanied by irreversible impairment of pancreatic internal and external secretory functions. Pathologically, atrophy of the pancreatic acini, tissue fibrosis or calcification, f...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Bing-Qing, Liu, Xin-Yuan, Mao, Tao, Zheng, Tao-Hua, Zhang, Peng, Zhang, Qi, Zhang, Yu, Li, Xiao-Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730810/
https://www.ncbi.nlm.nih.gov/pubmed/36505827
http://dx.doi.org/10.3389/fonc.2022.1050274
_version_ 1784845764124475392
author Li, Bing-Qing
Liu, Xin-Yuan
Mao, Tao
Zheng, Tao-Hua
Zhang, Peng
Zhang, Qi
Zhang, Yu
Li, Xiao-Yu
author_facet Li, Bing-Qing
Liu, Xin-Yuan
Mao, Tao
Zheng, Tao-Hua
Zhang, Peng
Zhang, Qi
Zhang, Yu
Li, Xiao-Yu
author_sort Li, Bing-Qing
collection PubMed
description Chronic pancreatitis (CP) is a chronic progressive inflammatory disease of the pancreas, caused by multiple factors and accompanied by irreversible impairment of pancreatic internal and external secretory functions. Pathologically, atrophy of the pancreatic acini, tissue fibrosis or calcification, focal edema, inflammation, and necrosis are observed. Clinical manifestations include recurrent or persistent abdominal pain, diarrhea, emaciation, and diabetes. In addition, CP is prone to develop into pancreatic cancer(PC) due to persistent inflammation and fibrosis. The disease course is prolonged and the clinical prognosis is poor. Currently, clinical treatment of CP is still based on symptomatic treatment and there is a lack of effective etiological treatment. Encouragingly, experiments have shown that a variety of active substances have great potential in the etiological treatment of chronic pancreatitis. In this paper, we will review the pathogenesis of CP, as well as the research progress on anti-inflammatory and anti-fibrotic therapies, which will provide new ideas for the development of subsequent clinical studies and formulation of effective treatment programs, and help prevent CP from developing into pancreatic cancer and reduce the prevalence of PC as much as possible.
format Online
Article
Text
id pubmed-9730810
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97308102022-12-09 The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis Li, Bing-Qing Liu, Xin-Yuan Mao, Tao Zheng, Tao-Hua Zhang, Peng Zhang, Qi Zhang, Yu Li, Xiao-Yu Front Oncol Oncology Chronic pancreatitis (CP) is a chronic progressive inflammatory disease of the pancreas, caused by multiple factors and accompanied by irreversible impairment of pancreatic internal and external secretory functions. Pathologically, atrophy of the pancreatic acini, tissue fibrosis or calcification, focal edema, inflammation, and necrosis are observed. Clinical manifestations include recurrent or persistent abdominal pain, diarrhea, emaciation, and diabetes. In addition, CP is prone to develop into pancreatic cancer(PC) due to persistent inflammation and fibrosis. The disease course is prolonged and the clinical prognosis is poor. Currently, clinical treatment of CP is still based on symptomatic treatment and there is a lack of effective etiological treatment. Encouragingly, experiments have shown that a variety of active substances have great potential in the etiological treatment of chronic pancreatitis. In this paper, we will review the pathogenesis of CP, as well as the research progress on anti-inflammatory and anti-fibrotic therapies, which will provide new ideas for the development of subsequent clinical studies and formulation of effective treatment programs, and help prevent CP from developing into pancreatic cancer and reduce the prevalence of PC as much as possible. Frontiers Media S.A. 2022-11-24 /pmc/articles/PMC9730810/ /pubmed/36505827 http://dx.doi.org/10.3389/fonc.2022.1050274 Text en Copyright © 2022 Li, Liu, Mao, Zheng, Zhang, Zhang, Zhang and Li https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Li, Bing-Qing
Liu, Xin-Yuan
Mao, Tao
Zheng, Tao-Hua
Zhang, Peng
Zhang, Qi
Zhang, Yu
Li, Xiao-Yu
The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis
title The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis
title_full The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis
title_fullStr The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis
title_full_unstemmed The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis
title_short The research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis
title_sort research progress of anti-inflammatory and anti-fibrosis treatment of chronic pancreatitis
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730810/
https://www.ncbi.nlm.nih.gov/pubmed/36505827
http://dx.doi.org/10.3389/fonc.2022.1050274
work_keys_str_mv AT libingqing theresearchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis
AT liuxinyuan theresearchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis
AT maotao theresearchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis
AT zhengtaohua theresearchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis
AT zhangpeng theresearchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis
AT zhangqi theresearchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis
AT zhangyu theresearchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis
AT lixiaoyu theresearchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis
AT libingqing researchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis
AT liuxinyuan researchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis
AT maotao researchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis
AT zhengtaohua researchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis
AT zhangpeng researchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis
AT zhangqi researchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis
AT zhangyu researchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis
AT lixiaoyu researchprogressofantiinflammatoryandantifibrosistreatmentofchronicpancreatitis